New CAR-T cell strategy aims to control tough leukemia with less chemo
NCT ID NCT06481228
Summary
This study is testing a new treatment plan for adults newly diagnosed with a specific, aggressive type of blood cancer called Philadelphia-positive acute lymphoblastic leukemia. The plan uses a combination of targeted pills, a short course of chemotherapy, and a one-time infusion of the patient's own genetically modified immune cells (CAR-T cells). The goal is to see if this approach can control the cancer effectively while reducing the need for many cycles of harsh chemotherapy, potentially improving survival and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.